Company news

Zelira Therapeutics Ltd. news in 2022

Zelira Therapeutics Ltd.'s news releases, calls and decks from 2022, newest first.

View company

ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial

November 20, 2022

September 2022 Quarterly Activities Report

October 30, 2022

ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled

September 14, 2022

Response to ASX Aware Query

August 5, 2022

June 2022 Quarterly Activities Report

July 28, 2022

Zenivol receives formal BfArM approval in Germany

July 12, 2022

Response to ASX Price Query

July 12, 2022

Pause in Trading

July 12, 2022

EDCDM Technology License Agreement Update

June 13, 2022

Zenivol Longitudinal, RWD Trial in Insomnia Results

June 7, 2022

Hope 1 Longitudinal, Real-World Data Trial in ASD Results

May 16, 2022

March 2022 Quarterly Activities Report

April 28, 2022

Appendix 4D & FY22 Interim Financial Report

February 28, 2022

ZLD: Zelira to acquire Health House International Limited

February 23, 2022

Zelira Therapeutics Ltd to acquire Health House

February 23, 2022

Appendix 4D & FY22 Interim Financial Report

February 23, 2022

December 2021 Quarterly Activities Report

January 30, 2022

Zelira receives $1.2 million cash R&D Tax Incentive

January 11, 2022

Partial Receipt Of Zeliras EDCDM Technology License Fee

January 9, 2022

Decks in 2022